Fennec Pharmaceuticals (STU:RV41) Cyclically Adjusted Book per Share: €0.52 (As of Mar. 2026)


STU:RV41 Fennec Pharmaceuticals Inc STU:RV41
59 GF Score
Price €9.25
GF Value €9.09
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Fennec Pharmaceuticals Cyclically Adjusted Book per Share?

Fennec Pharmaceuticals STU:RV41 +12.80% 59 Cyclically Adjusted Book per Share is €0.52 as of Mar. 2026. GuruFocus rates STU:RV41 with a GF Score™ of 59/100 and a GF Value™ of €9.09 (Fairly Valued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Fennec Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was €0.943. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.52 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Fennec Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 9.30% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 5.30% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 10.30% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -0.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Fennec Pharmaceuticals was 41.90% per year. The lowest was -62.50% per year. And the median was -23.10% per year.

As of today (2026-07-13), Fennec Pharmaceuticals's current stock price is €9.25. Fennec Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €0.52. Fennec Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 17.79.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Fennec Pharmaceuticals was 23.75. The lowest was 7.43. And the median was 15.49.


Fennec Pharmaceuticals  (STU:RV41) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Fennec Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=9.25/0.52
=17.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Fennec Pharmaceuticals was 23.75. The lowest was 7.43. And the median was 15.49.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Fennec Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Fennec Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Fennec Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fennec Pharmaceuticals Cyclically Adjusted Book per Share Chart

Fennec Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.39 0.45 0.48 0.49 0.46

Fennec Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 0.46 0.44 0.46 0.52

STU:RV41 vs VRTX, REGN, ALNY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Fennec Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fennec Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Fennec Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


STU:RV41
59GF Score
Fennec Pharmaceuticals Inc STU:RV41
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fennec Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Fennec Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.943/330.2130*330.2130
=0.943

Current CPI (Mar. 2026) = 330.2130.

Fennec Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.304 241.018 0.417
201609 0.276 241.428 0.377
201612 0.248 241.432 0.339
201703 0.196 243.801 0.265
201706 0.551 244.955 0.743
201709 0.469 246.819 0.627
201712 1.228 246.524 1.645
201803 1.126 249.554 1.490
201806 1.132 251.989 1.483
201809 1.025 252.439 1.341
201812 0.942 251.233 1.238
201903 0.854 254.202 1.109
201906 0.733 256.143 0.945
201909 0.685 256.759 0.881
201912 0.537 256.974 0.690
202003 0.385 258.115 0.493
202006 1.265 257.797 1.620
202009 1.026 260.280 1.302
202012 0.919 260.474 1.165
202103 0.805 264.877 1.004
202106 0.711 271.696 0.864
202109 0.621 274.310 0.748
202112 0.537 278.802 0.636
202203 0.437 287.504 0.502
202206 0.310 296.311 0.345
202209 0.108 296.808 0.120
202212 -0.092 296.797 -0.102
202303 -0.260 301.836 -0.284
202306 -0.339 305.109 -0.367
202309 -0.374 307.789 -0.401
202312 -0.394 306.746 -0.424
202403 0.102 312.332 0.108
202406 -0.046 314.175 -0.048
202409 -0.170 315.301 -0.178
202412 -0.204 315.605 -0.213
202503 -0.197 319.799 -0.203
202506 -0.233 322.561 -0.239
202509 -0.136 324.800 -0.138
202512 0.887 324.054 0.904
202603 0.943 330.213 0.943

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €0.52 mean?
Fennec Pharmaceuticals (STU:RV41) has a Cyclically Adjusted Book per Share of €0.52 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Fennec Pharmaceuticals and its competitors.
Is Fennec Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Fennec Pharmaceuticals' current Cyclically Adjusted Book per Share is €0.52. Overall, Fennec Pharmaceuticals has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fennec Pharmaceuticals' Cyclically Adjusted Book per Share compare to VRTX and REGN?
Fennec Pharmaceuticals' Cyclically Adjusted Book per Share of €0.52 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Fennec Pharmaceuticals and its competitors. Fennec Pharmaceuticals's current Cyclically Adjusted Book per Share is €0.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fennec Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Fennec Pharmaceuticals (STU:RV41) is currently considered Fairly Valued. The stock's GF Value™ is €9.09, compared to a current price of €9.25 — trading 1.8% above its estimated fair value. The current Cyclically Adjusted Book per Share is €0.52. Fennec Pharmaceuticals' overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Fennec Pharmaceuticals (STU:RV41), the current Cyclically Adjusted Book per Share is €0.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fennec Pharmaceuticals (STU:RV41) Overvalued in 2026?

Based on GuruFocus' analysis, Fennec Pharmaceuticals stock appears to be overvalued. The current stock price of €9.25 is trading 1.8% above its estimated GF Value™ of €9.09. GuruFocus considers Fennec Pharmaceuticals to be Fairly Valued.

Key valuation signals for STU:RV41:

  • Cyclically Adjusted Book per Share: €0.52
  • GF Value™: €9.09 vs. price of €9.25 (1.8% above fair value)
  • GF Score™: 59/100 with 2 warning signs

No single metric tells the full story. See the STU:RV41 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fennec Pharmaceuticals Business Description

Other Exchanges FENC:USAFRX:Canada
Address 68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
59GF Score

Get the complete analysis for STU:RV41

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.25
Price
€9.09
GF Value